New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:10 EDTGES, CIDM, BGMD, BURL, LEN, SNTA, GSK, FSLR, SSYS, DDD, XONE, TLYSOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Burlington Stores (BURL), up 5%... Lennar (LEN), up 2%... BG Medicine (BGMD), up 16%. ALSO HIGHER: Synta Pharmaceuticals (SNTA), up 20% after announcing positive interim results from ganetespib trial... First Solar (FSLR), up 3.5% after the company's price target was raised at Deutsche Bank, JPMorgan and RW Baird following the company issued it FY15 outlook yesterday. DOWN AFTER EARNINGS: Guess (GES), down 5%... Tilly's (TLYS), down 7%... ExOne (XONE), down 12%. Peers in 3D space down as well, with 3D Systems down 3% and Stratasys (SSYS) down 2%. ALSO LOWER: Agenus (AGEN), down 18% after announcing that GlaxoSmithKline’s (GSK) MAGRIT study, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint... Cinedigm Digital (CIDM), down 12% after filing to sell common stock.
News For GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS From The Last 14 Days
Check below for free stories on GES;XONE;DDD;SSYS;FSLR;GSK;SNTA;LEN;BURL;BGMD;CIDM;TLYS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 22, 2014
14:19 EDTGSKViiV Healthcare receives FDA approval for HIV-1 treatment Triumeq
Subscribe for More Information
12:08 EDTGESGap hits 52-week high following beat and raise quarter
Shares of specialty apparel retailer The Gap (GPS) are advancing after the company posted better than expected second quarter results, and raised its fiscal 2014 profit outlook. WHAT'S NEW: Last night, Gap reported Q2 earnings per share of 75c and revenue of $3.98B, topping analysts’ consensus estimates of 69c and $3.96B, respectively. Q2 same store sales were flat versus the prior year period. WHAT’S NOTABLE: For FY14, Gap raised its EPS view to $2.95-$3.00 from $2.90-$2.95, versus consensus of $2.95. The company updated its guidance for FY14 diluted EPS to reflect the 5c related to the gain on asset sale. For FY14, the company continues to expect capital spending to be approximately $750M in support of its outlined strategies. Gap also announced it will enter India through franchise-operated Gap brand stores in 2015. Gap is partnering with Arvind Lifestyle Brand Limited, a subsidiary of Arvind Limited, which is one of India’s largest textile companies. The first stores are expected to open in India’s two largest cities – Mumbai and Delhi – starting with Gap’s Summer 2015 collection for adults, kids and babies. The brand plans to open about 40 franchise-operated Gap stores in India. ANALYST REACTION: This morning, analyst commentary was decidedly positive. Research firm Janney Capital upgraded Gap to Buy from Neutral. The firm upgraded shares based on the overall improving Softlines sector due to an inventory correction, Old Navy strength, global opportunities, potential improved gross margin returns on inventory investment, and best-in-class management. Their price target on the shares is $51. Another firm, UBS, said Gap is well positioned for second half upside citing its Omni-channel advantage, shift to higher margin businesses, increased square footage, and modestly positive comps driven by ecommerce. UBS has a Buy rating and a $50 price target on the stock. Sterne Agee says Gap’s valuation is very attractive. The firm believes that Gap's fundamentals are improving, while the setup for the stock over the next 12-18 months is favorable. It adds that the company's gross margins should be boosted by several factors going forward, and it kept a Buy rating on the shares. PRICE ACTION: In late morning trading, Gap rose $2.04, or 4.7%, to $45.22 on heavy trading volume. Earlier in the session, it reached a new 52-week high of $45.47. Including today’s advance, the stock has gained over 7.5% over the past twelve months. OTHERS TO WATCH: Other specialty apparel companies include Abercrombie & Fitch (ANF), American Eagle Outfitters (AEO), Guess (GES), and The Buckle (BKE).
10:06 EDTGESGuess upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
August 21, 2014
10:07 EDTGESGuess falls after Chief Design Officer latest to leave
Subscribe for More Information
09:07 EDTGESOn The Fly: Pre-market Movers
Subscribe for More Information
06:43 EDTGESGuess management turnover concerning, says Piper Jaffray
Piper Jaffray says it remains concerned with the continued pattern of management turnover at Guess after the company disclosed the departure of its Chief Design Officer. Piper believes it will take longer to turn around the Guess brand and keeps a Neutral rating on the stock.
06:40 EDTGESGuess discloses resignation of Chief Design Officer
Subscribe for More Information
August 20, 2014
15:35 EDTGSKGlaxoSmithKline receives FDA approval for Arnuity Ellipta in the U.S.
Subscribe for More Information
12:20 EDTCIDMRonald Chez sends letter to Cinedigm over insider ownership
Subscribe for More Information
11:44 EDTGSKMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
08:30 EDTGSKPernix closes acquisition of Treximet
Subscribe for More Information
08:29 EDTGSKPernix Therapeutics to host conference call
Conference call to discuss acquisition of Treximet will be held on August 20 at 9 am. Webcast Link
08:04 EDTGSKPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
07:23 EDTSSYSBrean Capital remains a buyer of Stratasys following management meetings
Subscribe for More Information
August 19, 2014
10:13 EDTGESOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CNOOC (CEO) downgraded to Hold from Buy at Jefferies... Guess (GES) downgraded to Neutral from Overweight at Piper Jaffray... Ingersoll-Rand (IR) downgraded at RW Baird... Lehigh Gas (LGP) downgraded to Neutral from Buy at Ladenburg... Lexicon (LXRX) downgraded to Hold from Buy at Gabelli... Monster Beverage (MNST) downgraded to Neutral from Buy at SunTrust... Nobel Biocare (NBHGY) downgraded to Hold from Buy at Berenberg... Saint Joe Co. (JOE) downgraded to Market Perform from Outperform at Raymond James... SolarCity (SCTY) downgraded at RW Baird.
06:12 EDTGESGuess downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Guess to Neutral saying the company's turnaround could take more time to play out.
August 15, 2014
08:25 EDTXONEExOne Q2 hurt by one-time costs, says FBR Capital
Subscribe for More Information
07:43 EDTXONEExOne price target lowered to $21 from $25 at Credit Suisse
Credit Suisse lowered ExOne's price target to $21 and reiterated its Underperform rating following the Q2 miss. The firm is troubled by gross margin guidance, deteriorating cash position, difficult ales guidance, and competitive metal 3D printing technologies.
06:42 EDTCIDMCinedigm management to meet with Piper Jaffray
Subscribe for More Information
06:34 EDTGSKLawyer says GSK connected investigators to not appeal ruling, Reuters says
Defense lawyer Zhai Jian said GlaxoSmithKline connected corporate investigator Peter Humphrey and his American wife are not aiming to appeal a Chinese court's prison sentence ruling, according to Reuters, citing comments from Jian. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use